CanSino Biologics Inc. (www.cansinotech.com) is a global vaccine company based in China and is a dynamic biotech leader blazing new paths in R&D, manufacturing, and commercialisation of vaccine products for human use. CanSinoBIO currently has 15 vaccine candidates for 12 disease areas. Among them, the Company’s globally innovative vaccine Ad5-EBOV is the first approved Ebola virus disease vaccine in China for emergency use and national stockpile. The company's two new meningococcal conjugate vaccines are nearing commercialization. The clinical trial of the innovative TB Booster vaccine is being conducted in Canada. CanSinoBIO also has innovative pneumococcal vaccine candidate PBPV in the development. All of the vaccine products developed and manufactured at CanSinoBio facility in Tianjin are in full compliance with US, EU and China GMP regulations.